DE60234092D1 - Agonisten und antagonisten von sphingosin-1-phosphatrezeptoren - Google Patents
Agonisten und antagonisten von sphingosin-1-phosphatrezeptorenInfo
- Publication number
- DE60234092D1 DE60234092D1 DE60234092T DE60234092T DE60234092D1 DE 60234092 D1 DE60234092 D1 DE 60234092D1 DE 60234092 T DE60234092 T DE 60234092T DE 60234092 T DE60234092 T DE 60234092T DE 60234092 D1 DE60234092 D1 DE 60234092D1
- Authority
- DE
- Germany
- Prior art keywords
- sub
- sphingosin
- agonists
- antagonists
- alkenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6503—Five-membered rings
- C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
- C07F9/65068—Five-membered rings having the nitrogen atoms in positions 1 and 3 condensed with carbocyclic rings or carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
- C07F9/3804—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se) not used, see subgroups
- C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26492701P | 2001-01-30 | 2001-01-30 | |
US32781401P | 2001-10-09 | 2001-10-09 | |
PCT/US2002/002715 WO2002064616A2 (en) | 2001-01-30 | 2002-01-30 | Agonists and antagonists of sphingosine-1-phosphate receptors |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60234092D1 true DE60234092D1 (de) | 2009-12-03 |
Family
ID=26950835
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60234092T Expired - Fee Related DE60234092D1 (de) | 2001-01-30 | 2002-01-30 | Agonisten und antagonisten von sphingosin-1-phosphatrezeptoren |
Country Status (8)
Country | Link |
---|---|
US (1) | US7064217B2 (de) |
EP (1) | EP1383778B1 (de) |
JP (1) | JP2004529100A (de) |
AT (1) | ATE446303T1 (de) |
AU (1) | AU2002237988B2 (de) |
CA (1) | CA2437358A1 (de) |
DE (1) | DE60234092D1 (de) |
WO (1) | WO2002064616A2 (de) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2003020313A1 (ja) * | 2001-09-04 | 2004-12-16 | 小野薬品工業株式会社 | スフィンゴシン−1−リン酸受容体調節剤からなる呼吸器疾患治療剤 |
ITRM20010688A1 (it) | 2001-11-21 | 2003-05-21 | Univ Roma | Composti immunoregolatori. |
GB0217152D0 (en) | 2002-07-24 | 2002-09-04 | Novartis Ag | Organic compounds |
WO2004010949A2 (en) | 2002-07-30 | 2004-02-05 | University Of Virginia Patent Foundation | Compounds active in spinigosine 1-phosphate signaling |
BR0314455A (pt) | 2002-09-19 | 2005-07-26 | Kyorin Seiyaku Kk | Derivados de aminoálcool, seus sais e agentes imunosupressores |
EP2172472B1 (de) * | 2003-02-18 | 2012-12-26 | Kyorin Pharmaceutical Co., Ltd. | Aminophosphonsäurederivat, Salz davon und S1P-Rezeptormodulator |
JP4944613B2 (ja) * | 2003-05-19 | 2012-06-06 | アイアールエム・リミテッド・ライアビリティ・カンパニー | 免疫抑制化合物および組成物 |
EP1481680A1 (de) * | 2003-05-30 | 2004-12-01 | Aventis Pharma Deutschland GmbH | Verwendung von S1P |
US7638637B2 (en) * | 2003-11-03 | 2009-12-29 | University Of Virginia Patent Foundation | Orally available sphingosine 1-phosphate receptor agonists and antagonists |
GB0401332D0 (en) * | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
MX2007000564A (es) * | 2004-07-16 | 2007-03-30 | Kyorin Seiyaku Kk | Metodo para utilizar efectivamente medicamentos referentes a la prevencion de efectos secundarios. |
US20090202987A1 (en) * | 2004-07-27 | 2009-08-13 | Mandala Suzanne M | Canis sphingosine 1-phosphate receptor isoform 2 |
EP1781595A1 (de) * | 2004-08-13 | 2007-05-09 | Praecis Pharmaceuticals Inc. | Verfahren und zusammensetzungen zur modulation von sphingosin-1-phosphat-rezeptoraktivität |
US20060223866A1 (en) * | 2004-08-13 | 2006-10-05 | Praecis Pharmaceuticals, Inc. | Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity |
PL1806338T3 (pl) * | 2004-10-12 | 2016-07-29 | Kyorin Seiyaku Kk | Sposób wytwarzania chlorowodorku 2-amino-2-[2-[4-(3-benzyloksyfenylotio)-2-chlorofenyio]etylo]-1,3-propanodioiu i jego hydratów oraz produkty pośrednie w ich wytwarzaniu |
EP1827606A2 (de) * | 2004-12-06 | 2007-09-05 | University Of Virginia Patent Foundation | Arylamid-sphingosin-1-phosphat-analoga |
US7754703B2 (en) | 2005-02-14 | 2010-07-13 | University Of Virginia Patent Foundation | Cycloalkane-containing sphingosine 1-phosphate agonists |
GB0513431D0 (en) | 2005-06-30 | 2005-08-10 | Kherion Technology Ltd | Prophylactic compositions and uses |
WO2007043433A1 (ja) * | 2005-10-07 | 2007-04-19 | Kyorin Pharmaceutical Co., Ltd. | 2-アミノ-1,3-プロパンジオール誘導体を有効成分とする肝臓疾患治療剤および肝臓疾患治療方法 |
JP5140854B2 (ja) | 2005-10-12 | 2013-02-13 | トーアエイヨー株式会社 | S1p3受容体拮抗剤 |
US7919519B2 (en) | 2005-11-23 | 2011-04-05 | Epix Pharmaceuticals Inc. | S1P receptor modulating compounds and use thereof |
WO2007061458A2 (en) * | 2005-11-23 | 2007-05-31 | Epix Delaware, Inc. | S1p receptor modulating compounds and use thereof |
EP1986623A2 (de) * | 2006-01-27 | 2008-11-05 | University Of Virginia Patent Foundation | Verfahren zur behandlung von neuropathischem schmerz |
TWI389683B (zh) * | 2006-02-06 | 2013-03-21 | Kyorin Seiyaku Kk | A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient |
WO2007092638A1 (en) * | 2006-02-09 | 2007-08-16 | University Of Virginia Patent Foundation | Bicyclic sphingosine 1-phosphate analogs |
US7790707B2 (en) | 2006-03-21 | 2010-09-07 | Epix Pharmaceuticals Inc. | S1P receptor modulating compounds and use thereof |
MY146775A (en) * | 2006-08-08 | 2012-09-28 | Kyorin Seiyaku Kk | Amino alcohol derivative and immunosuppressive agent having same as an active ingredient |
DK2058317T3 (da) * | 2006-08-08 | 2014-01-06 | Kyorin Seiyaku Kk | Aminophosphorsyreesterderivat og S1P receptormodulator indeholdende samme som aktiv ingrediens |
WO2008064337A2 (en) * | 2006-11-21 | 2008-05-29 | University Of Virginia Patent Foundation | Benzocycloheptyl analogs having sphingosine 1-phosphate receptor activity |
JP2010510249A (ja) | 2006-11-21 | 2010-04-02 | ユニバーシティ オブ バージニア パテント ファンデーション | スフィンゴシン=1−燐酸アゴニスト活性を有するテトラリンアナログ |
JP2010510250A (ja) * | 2006-11-21 | 2010-04-02 | ユニバーシティ オブ バージニア パテント ファンデーション | スフィンゴシン=1−燐酸受容体アゴニスト活性を有するヒドリンダンアナログ |
EP2142184B1 (de) * | 2007-05-04 | 2018-10-24 | Novartis AG | Verwendung des s1p-rezeptormodulators |
CN101358609A (zh) * | 2007-08-03 | 2009-02-04 | 富准精密工业(深圳)有限公司 | 风扇转子 |
MX2010002885A (es) | 2007-09-20 | 2010-04-01 | Amgen Inc | Derivados de acido 1-(4-(bencilbenzamido)-bencil)-azetidin-3-carbo xilico y compuestos relacionados como moduladores de receptores de s1p para el tratamiento de trastornos inmunitarios. |
US8404863B2 (en) | 2008-01-03 | 2013-03-26 | Allergan, Inc. | Tetrahydroindoles having sphingosine-1-phosphate receptor activity |
TW200946105A (en) * | 2008-02-07 | 2009-11-16 | Kyorin Seiyaku Kk | Therapeutic agent or preventive agent for inflammatory bowel disease containing amino alcohol derivative as active ingredient |
US8212010B2 (en) * | 2008-02-25 | 2012-07-03 | Expression Drug Designs, Llc | Sphingosine 1-phosphate antagonism |
KR20190132565A (ko) | 2008-07-23 | 2019-11-27 | 아레나 파마슈티칼스, 인크. | 자가면역성 및 염증성의 장애의 치료에 유용한 치환된 1,2,3,4-테트라히드로시클로펜타[b]인돌-3-일)아세트산 유도체 |
CA2733970A1 (en) * | 2008-08-12 | 2010-02-18 | Allergan, Inc. | Sphingosine-1-phosphate (s1p) receptor antagonists and methods for use thereof |
CN105816453B (zh) | 2008-08-27 | 2021-03-05 | 艾尼纳制药公司 | 用于治疗自身免疫性病症和炎性病症的作为s1p1受体激动剂的经取代的三环酸衍生物 |
ES2466695T3 (es) | 2008-10-30 | 2014-06-11 | Biogen Idec Ma Inc. | Análogos de esfingosina 1-fosfato de arilo bicíclico |
US9181191B2 (en) | 2008-10-30 | 2015-11-10 | Biogen Ma Inc. | Heterobicyclic sphingosine 1-phosphate analogs |
US8349849B2 (en) * | 2008-10-30 | 2013-01-08 | Biogen Idec Ma Inc. | Heterobicyclic sphingosine 1-phosphate analogs |
WO2011028927A1 (en) * | 2009-09-04 | 2011-03-10 | Allergan, Inc. | Selective sphingosine-1-phosphate receptor antagonists |
ES2937386T3 (es) | 2010-01-27 | 2023-03-28 | Arena Pharm Inc | Procesos para la preparación de ácido (R)-2-(7-(4-ciclopentil-3-(trifluorometil)benciloxi)-1,2,3,4-tetrahidrociclopenta[b]indol-3-il)acético y sales del mismo |
CA2789480A1 (en) | 2010-03-03 | 2011-09-09 | Arena Pharmaceuticals, Inc. | Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof |
WO2014074805A1 (en) * | 2012-11-08 | 2014-05-15 | Whitehead Institute For Biomedical Research | Selective targeting of cancer stem cells |
US9771326B2 (en) * | 2012-11-20 | 2017-09-26 | Biogen Ma Inc. | S1P and/or ATX modulating agents |
US10398672B2 (en) | 2014-04-29 | 2019-09-03 | Whitehead Institute For Biomedical Research | Methods and compositions for targeting cancer stem cells |
WO2016112075A1 (en) | 2015-01-06 | 2016-07-14 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the s1p1 receptor |
SI3310760T1 (sl) | 2015-06-22 | 2023-02-28 | Arena Pharmaceuticals, Inc. | Kristalinična L-argininska sol (R)-2-(7-(4-ciklopentil-3-(trifluorometil)benziloksi)-1,2,3,4- tetrahidrociklo-penta(b)indol-3-il)ocetne kisline za uporabo pri motnjah, povezanih z receptorjem S1P1 |
AU2018222747A1 (en) | 2017-02-16 | 2019-09-05 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations |
CA3053418A1 (en) | 2017-02-16 | 2018-08-23 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of primary biliary cholangitis |
IL252151A0 (en) | 2017-05-07 | 2017-07-31 | Fainzilber Michael | Treatment of stress disorders |
CN112955431A (zh) | 2018-09-06 | 2021-06-11 | 艾尼纳制药公司 | 可用于治疗自身免疫性病症和炎性病症的化合物 |
CA3222167A1 (en) | 2021-05-31 | 2022-12-08 | Rena Therapeutics Inc. | Ligand-binding nucleic acid complex |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2548155A (en) * | 1948-10-02 | 1951-04-10 | Goodrich Co B F | Preparation of amides |
US3193458A (en) * | 1961-07-12 | 1965-07-06 | Us Vitamin Pharm Corp | Method of lowering blood cholesterol level |
US4906767A (en) * | 1987-06-30 | 1990-03-06 | The University Of Southern Mississippi | Monomers with urea groups |
US5219884A (en) * | 1988-09-14 | 1993-06-15 | Taito Co., Ltd. | Immunosuppressant |
DE4134156A1 (de) | 1991-10-11 | 1993-04-15 | Schering Ag | 9-substituierte bicyclo(3.3.0)octan-derivate, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung |
DE4225488A1 (de) | 1992-07-30 | 1994-02-03 | Schering Ag | Neue Bicyclo[3.3.0]octan-Derivate, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung |
ES2126658T3 (es) * | 1992-10-21 | 1999-04-01 | Yoshitomi Pharmaceutical | Compuesto de 2-amino-1,3-propanodiol e inmunosupresor. |
IT1271267B (it) | 1994-12-14 | 1997-05-27 | Valle Francesco Della | Ammidi di acidi mono e bicarbossilici con amminoalcoli,selettivamente attive sul recettore periferico dei cannabinoidi |
US5604988A (en) * | 1995-03-30 | 1997-02-25 | Costelloe; Paul M. | Multipurpose device for marking or placing a workpiece |
US5773475A (en) * | 1997-03-17 | 1998-06-30 | Research Corporation Technologies, Inc. | Anticonvulsant enantiomeric amino acid derivatives |
JP2000511173A (ja) * | 1996-05-27 | 2000-08-29 | 藤沢薬品工業株式会社 | 一酸化窒素産生阻害剤としての新規なインドリルおよびベンゾフラニルカルボキサミド |
DE69830756T2 (de) | 1997-04-04 | 2006-05-04 | Mitsubishi Pharma Corp. | 2-Aminopropan-1,3-diol-Verbindungen, ihre medizinische Anwendung und Zwischenprodukte zu ihrer Synthese |
US6239297B1 (en) * | 1997-09-11 | 2001-05-29 | Takara Shuzo Co., Ltd. | Sphingosine derivatives and medicinal composition |
US7157092B1 (en) * | 1998-06-30 | 2007-01-02 | Om Pharma | Acyl pseudodipeptides, preparation method and pharmaceutical compositions containing same |
WO2001003739A1 (fr) | 1999-07-12 | 2001-01-18 | Ono Pharmaceutical Co., Ltd. | Inhibiteurs de fibrose contenant comme ingredient actif l'agoniste du recepteur de sphingosine-1-phosphate ou la sphingosine-1-phosphate |
CA2399683A1 (en) | 2000-02-07 | 2001-08-09 | Merck & Co., Inc. | Mammalian sphingosine-1-phosphate phosphatase |
ATE420878T1 (de) | 2000-02-18 | 2009-01-15 | Kyowa Hakko Kirin Co Ltd | Isoxazol- und thiazolverbindungen und ihre verwendung als medikamente |
JP2004506604A (ja) | 2000-03-17 | 2004-03-04 | ザ・ユニバーシティ・オブ・テネシー・リサーチ・コーポレイション | Lpa受容体作用薬および拮抗薬ならびにこれらの使用法 |
WO2001098301A1 (fr) | 2000-06-20 | 2001-12-27 | Japan Tobacco Inc. | Composes de pyrazolopyridine et utilisation de ces derniers en tant que medicaments |
AU6950301A (en) | 2000-07-13 | 2002-01-30 | Sankyo Co | Amino alcohol derivatives |
CA2421893A1 (en) | 2000-08-31 | 2002-03-07 | Merck And Co., Inc. | Phosphate derivatives as immunoregulatory agents |
AU2001288671A1 (en) | 2000-09-01 | 2002-03-13 | Neuronyx, Inc. | Novel synthetic gangliosides |
US20050070506A1 (en) | 2002-01-18 | 2005-03-31 | Doherty George A. | Selective s1p1/edg1 receptor agonists |
-
2002
- 2002-01-30 CA CA002437358A patent/CA2437358A1/en not_active Abandoned
- 2002-01-30 AU AU2002237988A patent/AU2002237988B2/en not_active Ceased
- 2002-01-30 US US10/470,820 patent/US7064217B2/en not_active Expired - Lifetime
- 2002-01-30 WO PCT/US2002/002715 patent/WO2002064616A2/en active Application Filing
- 2002-01-30 JP JP2002564545A patent/JP2004529100A/ja active Pending
- 2002-01-30 DE DE60234092T patent/DE60234092D1/de not_active Expired - Fee Related
- 2002-01-30 EP EP02704296A patent/EP1383778B1/de not_active Expired - Lifetime
- 2002-01-30 AT AT02704296T patent/ATE446303T1/de not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
WO2002064616A3 (en) | 2002-11-14 |
AU2002237988B2 (en) | 2008-01-03 |
EP1383778A4 (de) | 2005-03-09 |
EP1383778B1 (de) | 2009-10-21 |
EP1383778A2 (de) | 2004-01-28 |
ATE446303T1 (de) | 2009-11-15 |
WO2002064616A2 (en) | 2002-08-22 |
JP2004529100A (ja) | 2004-09-24 |
US7064217B2 (en) | 2006-06-20 |
US20040110728A1 (en) | 2004-06-10 |
CA2437358A1 (en) | 2002-08-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60234092D1 (de) | Agonisten und antagonisten von sphingosin-1-phosphatrezeptoren | |
ATE380187T1 (de) | Agonisten und antagonisten für den lpa-rezeptor und anwendungsmethoden | |
ATE318267T1 (de) | Einige alkylendiamin-substituierte heterocyclen | |
MY147730A (en) | Metabotropic glutamate receptor antagonists | |
DK1628685T3 (da) | Antivirale phosphonatanaloge | |
DE60220422D1 (de) | Substituierte pyrazoloverbindungen zur behandlung von entzündungen | |
ECSP045229A (es) | Piridinonas sustituidas como moduladores de la p38 map quinasa | |
WO2005002626A3 (en) | Therapeutic phosphonate compounds | |
BR9916282A (pt) | Composto, uso de um um composto e método de tratamento | |
BRPI0000596B8 (pt) | composto piridona, processo de produção do composto, composição farmacêutica, e uso do dito composto | |
BRPI0409680A (pt) | análogos de fosfonato anti-cáncer | |
EA200000336A1 (ru) | Антагонисты рецептора витронектина | |
DE602004027409D1 (de) | Tetrahydrofuroä3,4-düdioxolverbindungen und zusammensetzungen und verfahren zur inhibierung der trombozytenaggregation | |
TR200101711T2 (tr) | Antihistaminik spiro bileşikler. | |
EA200000431A2 (ru) | Новые замещенные димерные соединения, способ их получения и фармацевтические композиции, содержащие их | |
EA200301317A1 (ru) | Производные аминохинолина и его применение в качестве лигандов аденозина a3 | |
TR200002932T2 (tr) | Azabisayklik 5HT1 Alıcı liganolları | |
ES2167617T3 (es) | Derivados de 1-bencenosulfonilpirrolidina como antagonistas del receptor de la bradiquinina. | |
NO20022977L (no) | Substituerte homopiperidinylbenzimidazolanaloger som fundiske relaksanter | |
BR0311970A (pt) | Novos compostos, seu uso e preparação | |
ATE148345T1 (de) | Therapeutische verwendung von phosphoryl-l-serin- n-acyl-sphingosin | |
DE69900297D1 (de) | Akarizid und insektizid wirksame, substituierte Pyrimidine und Verfahren zu ihrer Herstellung | |
BRPI0414511A (pt) | composto, composições farmacêuticas, e, uso de um composto | |
EA200200733A1 (ru) | Новые гетероарильные производные, их получение и применение | |
ATE314059T1 (de) | VERWENDUNG VON ßXYLYLOXY ALKYL AMINESß FÜR DIE BEHANDLUNG VON TINNITUS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |